Table 1

Ongoing and pending clinical trials of anticoagulation restart after intracranial hemorrhage

		Sponsor	Eligibility*	Intervention	Primary outcome measure	Follow-up period	Proposed sample size
SoSTART	NCT03153150	University of Edinburgh	All sICrH (ICH, non-aneurysmal SAH, IVH, SDH) with non-valvular AF and CHA₂DS₂-VASc ≥2	Oral anticoagulation (DOAC or VKA antagonist) versus no anticoagulation teatment	Composite event rate: acute coronary, non-fatal stroke or vascular death	1 year	800
ASPIRE	NCT03907046	Yale School of Medicine and Yale New Haven Hospital; NINDS	ICH (including IVH), 14–120 days prior, with non-valvular AF and CHA₂DS₂-VASc ≥2	Apixaban versus aspirin	Composite event rate: non-fatal hemorrhagic or ischemic stroke or death	1–3 years	700
STATICH	NCT03186729	Oslo University Hospital	sICH with antithrombotic indication; stratified by AF (anticoagulant arm) and not (antiplatelet arm)	Anticoagulant treatment versus no treatment	Symptomatic ICH	2 years	500
A3ICH	NCT03243175	University Hospital, Lille	sICH with non-valvular AF and CHA₂DS₂-VASc ≥2	Apixaban versus LAAC versus neither intervention (standard care with or without antithrombotic treatment)	Composite event rate: fatal and non-fatal, cardiovascular/cerebrovascular, ischemic/hemorrhagic, incracranial/extracranial	2 years	300
APACHE-AF	NCT02565693	UMC Utrecht	sICH (including IVH) on anticoagulant treatment	Apixaban versus no antithrombotic treatment	Composite event rate: non-fatal stroke or vascular death	12–72 months	100
ENRICH-AF	NCT03950076	Population Health Research Institute	sICrH (IPH, IVH, cSAH) or non-penetrating traumatic SDH, with non-valvular AF and CHA₂DS₂-VASc ≥2, >14 days ago	Edoxaban versus no anticoagulant	Composite stroke events: ischemic, hemorrhagic, unspecified	2 years	1200
RESTART-T	NCT04229758	University of Texas at Austin	Traumatic ICrH and provider intent to reinitiate DOAC therapy	DOAC at 1 vs 2 vs 4 weeks	Composite event rate: hemorrhagic and thromboembolic events	60 days	1100

*Broad summaries of primary eligibility criteria, excluding multiple inclusion and exclusion.
AF, atrial fibrillation; cSAH, convexal subarachnoid hemorrhage; DOAC, direct oral anticoagulant; ICrH, intracranial hemorrhage; IPH, intraparenchymal hemorrhage; IVH, intraventricular hemorrhage; LAAC, left atrial appendage closure; SDH, subdural hematoma; sICH, spontaneous intracerebral hemorrhage; VKA, vitamin K antagonist.